Li Junxi, Huang Yong, Chen Siyu, Song Danyang, Chen Yulan, Chang Yikun, Chen Jinwei, Zhang Wangjian, Yuan Jun, Du Zhicheng
Department of Medical Statistics, School of Public Health & Sun Yat-sen Global Health Institute & Center for Health Information Research, Sun Yat-sen University, Guangzhou, China.
Department of Immunization Programme Planning, Guangzhou Center for Disease Control and Prevention, Guangzhou, China.
Expert Rev Vaccines. 2025 Dec;24(1):601-611. doi: 10.1080/14760584.2025.2536086. Epub 2025 Jul 24.
China has yet to implement a nationwide two-dose vaccination strategy. This study assesses the real-world effectiveness of varicella vaccination in Guangzhou, where the policy recommends voluntary, self-funded administration of two doses of the live attenuated vaccine, to provide insights for optimizing vaccination strategies.
Using outbreak data from 2017 to 2022 across preschools, primary, and secondary schools, we employed a three-level matched case-control design (school, grade, and class) and applied conditional logistic regression to estimate the effectiveness of single-dose (VE1) and two-dose (VE2) vaccinations, incremental VE, and the effectiveness of emergency vaccination.
From 2017 to 2022, 1,058 varicella cases were included in the study, with a median age of 9.0 years. The effectiveness of a single-dose vaccine ranged from 45.8% to 46.7%, while the two-dose vaccine showed higher effectiveness (94.5% to 95.8%), with an incremental VE of 89.7% to 92.1%. VE1 decreased over time, whereas VE2 remained relatively high within five years after the booster dose, with the interval between doses having little effect on VE2. Emergency vaccination was effective for the first dose (78.0%-84.5%) and more effective for the second dose (87.2%-91.4%).
Single-dose varicella vaccination provides limited protection, whereas the two-dose regimen enhances effectiveness.
中国尚未实施全国性的两剂次疫苗接种策略。本研究评估了广州水痘疫苗的真实世界有效性,该政策建议自愿自费接种两剂次减毒活疫苗,以提供优化疫苗接种策略的见解。
利用2017年至2022年幼儿园、中小学的疫情数据,我们采用三级匹配病例对照设计(学校、年级和班级),并应用条件逻辑回归来估计单剂次(VE1)和两剂次(VE2)疫苗接种的有效性、增量VE以及应急接种的有效性。
2017年至2022年,该研究纳入了1058例水痘病例,中位年龄为9.0岁。单剂次疫苗的有效性在45.8%至46.7%之间,而两剂次疫苗显示出更高的有效性(94.5%至95.8%),增量VE为89.7%至92.1%。VE1随时间下降,而VE2在加强剂量后的五年内保持相对较高,剂量间隔对VE2影响不大。应急接种对第一剂有效(78.0%-84.5%),对第二剂更有效(87.2%-91.4%)。
单剂次水痘疫苗接种提供的保护有限,而两剂次接种方案可提高有效性。